SCHEMBL31401136

SCHEMBL31401136

O=[N+]([O-])c1ccc(F)cn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
POLB P06746 1/20 0.45
RAB9A P51151 1/20 0.41
SOS1 Q07889 1/20 0.41
HSPB1 P04792 3/20 0.41
MEN1 O00255 1/20 0.41
ALOX12 P18054 1/20 0.41
KMT2A Q03164 1/20 0.41
ATM Q13315 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.39
CHRNB2 P17787 2/20 0.38
CHRNA4 P43681 2/20 0.38
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL169463 1.00 MAPT (0.47) MAPTPOLBRAB9ASOS1HSPB1
SCHEMBL4460183 0.80 HSPB1 (0.59) MAPTPOLBRAB9ASOS1HSPB1
SCHEMBL27617961 0.80 HSPB1 (0.59) MAPTPOLBRAB9ASOS1HSPB1
SCHEMBL27803434 0.76 MAPT (0.49) MAPTPOLBRAB9ASMN1; SMN2CHRNB2
SCHEMBL29580092 0.76 MAPT (0.50) MAPTPOLBRAB9AHSPB1MEN1
SCHEMBL10936934 0.76 MAPT (0.50) MAPTPOLBRAB9AHSPB1MEN1
SCHEMBL20455513 0.75 P4HTM (0.56) MAPTPOLBSOS1MEN1ALOX12
SCHEMBL4474721 0.74 KMT2A (0.58) MAPTPOLBMEN1ALOX12KMT2A
SCHEMBL18617604 0.74 MAPT (0.47) MAPTPOLBRAB9AMEN1KMT2A
SCHEMBL17262089 0.74 MAPT (0.47) MAPTPOLBRAB9ASMN1; SMN2CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
WO-2025008058-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 WO disclosed